Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, is US Food and Drug Administration-approved for the treatment of a range of atopic conditions including atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyposis, as well as for treatment of prurigo nodularis. This evidence concerns the gene IL4 and eosinophilic esophagitis.